[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lewy-body-dementia-with-behavioral-disturbance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lewy-body-dementia-with-behavioral-disturbance":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100439080","parkinsons-disease-and-movement-disorders-clinical-database-100439080",false,"NCT04997642","Parkinson's Disease and Movement Disorders Clinical Database","Inclusion Criteria:\n\nAny person who receives medical care for the diagnosis of Parkinson's disease with mild cognitive impairment (MCI) or dementia may be eligible to participate in the research database. There are no limitations for database participation based on age, disease severity or presence of cognitive impairments, as long as the person is able to complete the research assessments.\n\nExclusion Criteria:\n\nAbsence of Parkinson's disease diagnosis. There are no limitations for database participation based on age, disease severity or presence of cognitive impairments, as long as the person is able to complete the research assessments.","ALL","18 Years",{"count":18,"type":19},250,"ESTIMATED","15 Years","OBSERVATIONAL","The research database contains demographic and family history information, longitudinal information on the clinical symptoms, neuropsychological profile and treatments, stored biological samples, and brain images of patients with Parkinson's disease and related disorders receiving care at the Parkinson's disease and Movement Disorders Center and the Hospital of the University of Pennsylvania.",[24,25,26,27],"Parkinson Disease","Parkinson Disease Dementia","Lewy Body Parkinson Disease","Lewy Body Dementia With Behavioral Disturbance","RECRUITING","2025-10-01",{"date":31,"type":32},"2025-10-07","ACTUAL",{"date":34,"type":32},"2019-09-30",{"date":36,"type":19},"2029-09-15",{"name":38,"class":39},"University of Pennsylvania","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100576488","tdcs-effect-on-psychotic-symptoms-in-dementia-with-lewy-bodies-dlb-and-impacts-on-caregiver-burden-100576488","NCT06785948","tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden","MCL-tDCS","Inclusion Criteria:\n\n* Male or Female, aged over 60,\n* Diagnosed with a neurodegenerative pathology of the DLB type, at a moderate stage, according to the McKeith and al. (2017) criteria\n* No change in antiparkinsonian or psychotropic medications, or cholinesterase inhibitors, for a period of one month prior to inclusion,\n* Mini Mental State Examination (MMSE) \\> 15,\n* Composite score called \"psychotic factor\" (corresponding to the sum of the psychotic-type symptoms sub-scores from the NPI \\[12\\]) greater than 0,\n* Presence of a family caregiver,\n* Sufficient written and oral expression in French,\n* Written informed consent signed by the patient and his\u002Fher family caregiver\n\nExclusion Criteria:\n\n* History of alcoholism, drug addiction or neurological diseases such as brain trauma, epilepsy, encephalitis, intracranial normal-pressure hydrocephalus, etc. which may lead to cognitive impairment,\n* Concomitant major psychiatric illness,\n* Significant physical illness or comorbidities\n* History of moderate to severe visual impairment secondary to glaucoma, cataract or macular degeneration,\n* Patient under guardianship or curators","60 Years",{"count":50,"type":19},30,"INTERVENTIONAL",[53],"NA","The goal of this pilot prospective study is to evaluate the effect of tDCS on psychotic-like symptoms in patients with Lewy Body Dementia (LBD). The main questions it aims to answer are:\n\n* What is the effect of tDCS on neuropsychiatric symptoms, especially psychotic-like symptoms?\n* What is the impact of tDCS on caregiver burden?\n\nResearchers will compare active tDCS (2mA stimulation, anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital) to Sham tDCS (placebo stimulation, no intensity applied) to see if there is an effect on reducing psychotic-like symptoms and on caregiver burden.\n\nParticipants will:\n\n* Undergo a stimulation phase consisting of 10 tDCS sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation).\n* perform assessments at T0 (inclusion), T1 (at the end of the stimulation phase), and T2 (follow-up at 8 weeks post stimulation).",[56,27,57,58,59],"Lewy Body Dementia","Burden, Caregiver","Lewy Body Disease","Dementia With Lewy Bodies",[61,62,63,64],"Transcranial Direct-Current Stimulation (t-DCS)","Brain stimulation","Psychotic symptoms","Caregiver burden","2025-09-30",{"date":29,"type":32},{"date":68,"type":32},"2025-01-10",{"date":70,"type":19},"2026-11",{"name":72,"class":39},"Association de Recherche Bibliographique pour les Neurosciences",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":15,"minAge":16,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":51,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100440413","telehealth-in-lewy-body-dementia-100440413","NCT05014971","Telehealth in Lewy Body Dementia","Multi-Stakeholder Engagement for Interdisciplinary Telehealth in Lewy Body Dementia","Participant with Lewy Body Dementia (LBD) Inclusion Criteria:\n\n* LBD diagnosis by a dementia or movement disorders specialist\n* Clinician-determined mild-moderate dementia severity\n* Internet access with a Zoom-compatible device\n* Caregiver who resides in the patient's home and is willing to participate\n* Fluency in English",true,"100 Years",{"count":83,"type":19},106,[53],"Lewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and physical, cognitive, and behavioral impairments making travel to appointments challenging. Delivering interdisciplinary care remotely using video technology has the potential to improve access to care for patients with LBD.",[27,26,58],"2025-06-25",{"date":89,"type":32},"2025-06-26",{"date":91,"type":32},"2022-02-28",{"date":93,"type":19},"2026-05-31",{"name":95,"class":39},"University of Florida"]